Mohamed Ghada Abdelrahman, Nashaat Ehab Hasan, Fawzy Hadeer Mohamed, ElGhandour Ahmed Mohamed
Department of Internal Medicine, Gastroenterology and Hepatology Unit, Faculty of Medicine, Ain Shams University, Cairo 11591, Egypt.
World J Hepatol. 2022 Mar 27;14(3):623-633. doi: 10.4254/wjh.v14.i3.623.
Fibroblast growth factor 19 (FGF-19) is one of the founding members of the endocrine FGF subfamily. Recently, it has been the subject of much interest owing to its role in various physiological processes affecting glucose and lipid metabolism and the regulation of bile acid secretion as well as cell proliferation, differentiation, and motility. Additionally, FGF-19 secretion in an autocrine style has reportedly contributed to cancer progression in various types of malignancies including hepatocellular carcinoma (HCC).
To estimate the serum FGF-19 concentrations in HCC cases and assess its diagnostic performance for the detection of HCC.
We recruited 90 adult participants and divided them into three equal groups: Healthy controls, cirrhosis patients, and HCC patients. Serum FGF-19 concentrations were measured using the Human FGF-19 ELISA kit.
We detected a high statistically significant difference in serum FGF-19 levels among the three groups. The highest level was observed in the HCC group, followed by the cirrhosis and control groups (236.44 ± 40.94 125.63 ± 31.54 69.60 ± 20.90 pg/mL, respectively, ≤ 0.001). FGF-19 was positively correlated with alpha fetoprotein (AFP; = 0.383, = 0.003) and international normalised ratio ( = 0.357, = 0.005), while it was negatively correlated with albumin ( = -0.500, ≤ 0.001). For the detection of HCC, receiver operating characteristic curve analysis showed that the best cut-off point of AFP was > 8.2 ng/mL with an area under the curve (AUC) of 0.78, sensitivity of 63.33%, specificity of 83.33%, positive predictive value (PPV) of 79.2%, negative predictive value (NPV) of 69.4%, and total accuracy of 78%. However, FGF-19 at a cut-off point > 180 pg/mL had an AUC of 0.98, sensitivity of 100%, specificity of 90.0%, PPV of 90.0%, NPV of 100%, and total accuracy of 98%.
FGF-19 represents a possible novel non-invasive marker for HCC. It may improve the prognosis of HCC patients due to its utility in several aspects of HCC detection and management.
成纤维细胞生长因子19(FGF - 19)是内分泌FGF亚家族的创始成员之一。最近,由于其在影响葡萄糖和脂质代谢的各种生理过程、胆汁酸分泌调节以及细胞增殖、分化和运动中的作用,它受到了广泛关注。此外,据报道,FGF - 19以自分泌方式分泌促进了包括肝细胞癌(HCC)在内的各种恶性肿瘤的癌症进展。
评估HCC患者血清FGF - 19浓度,并评估其对HCC检测的诊断性能。
我们招募了90名成年参与者,并将他们平均分为三组:健康对照组、肝硬化患者组和HCC患者组。使用人FGF - 19 ELISA试剂盒测量血清FGF - 19浓度。
我们检测到三组之间血清FGF - 19水平存在高度统计学显著差异。HCC组水平最高,其次是肝硬化组和对照组(分别为236.44±40.94、125.63±31.54、69.60±20.90 pg/mL,≤0.001)。FGF - 19与甲胎蛋白(AFP; = 0.383, = 0.003)和国际标准化比值( = 0.357, = 0.005)呈正相关,而与白蛋白呈负相关( = -0.500,≤0.001)。对于HCC的检测,受试者工作特征曲线分析表明,AFP的最佳截断点> 8.2 ng/mL,曲线下面积(AUC)为0.78,灵敏度为63.33%,特异性为83.33%,阳性预测值(PPV)为!79.2%,阴性预测值(NPV)为69.4%,总准确率为78%。然而,FGF - 19截断点> 180 pg/mL时,AUC为0.98,灵敏度为100%,特异性为90.0%,PPV为90.0%,NPV为100%,总准确率为98%。
FGF - 19是一种可能的新型HCC非侵入性标志物。由于其在HCC检测和管理的多个方面的效用,它可能改善HCC患者的预后。